Philip Bonomi to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Philip Bonomi has written about Drug Screening Assays, Antitumor.
Connection Strength
0.078
-
Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401.
Score: 0.059
-
Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest. 1997; 15(4):358-68.
Score: 0.009
-
An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 1996 Sep-Oct; 16(5A):2589-99.
Score: 0.009